Business
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. “We a
About this update from Kestra Medical Technologies, Ltd.
[{"type":"image","alt":"InspireMD Inc.","displaySize":"","headline":null,"caption":"InspireMD Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":206,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/de2f14a2bd34f4c4ce9ff024cee316df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_AZpeZW_vtC.eOzsQRByqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTczO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/de2f14a2bd34f4c4ce9ff024cee316df","width":206,"height":42}},"lazy":false},{"type":"text","content":"MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions.","length":494,"tagName":"p"},{"type":"text","content":"“We are thrilled to welcome Ray to InspireMD’s Board of Directors,” said Marvin Slosman, Chief Executive Officer of InspireMD. “We expect to benefit greatly from his vast insights and experience. His operational acumen, strategic vision, and experience driving transformative growth brings a unique perspective that will strengthen our execution and sharpen our long-term value-creation strategy. Following the recent PMA approval of our CGuard Prime carotid stent system, we have quickly shifted our focus to our commercial launch and providing our CGuard Prime therapy to patients and we look forward to working with Ray to enable these goals.”","length":646,"tagName":"p"},{"type":"text","content":"Mr. Cohen was the CEO and co-founder of Axonics, Inc., which he took public in late 2018 and led through its $3.7 billion acquisition by Boston Scientific in November 2024. Axonics earned recognition as the number one fastest-growing company in the Americas by Deloitte and the Financial Times in 2021.","length":302,"tagName":"p"},{"type":"text","content":"Until May of 2025, Mr. Cohen served as Chairman of SoniVie Ltd., a clinical stage company focused on a device treatment for hypertension until it was acquired by Boston Scientific for $600 million. Cohen also serves as an independent director...